Exploration of the DPP-4 inhibitors with a focus on saxagliptin

被引：5

作者：

Shubrook, Jay H. ^{[1
]}

Colucci, Randall A. ^{[1
]}

Schwartz, Frank L. ^{[2
]}

机构：

[1] Ohio Univ, Coll Osteopath Med, Athens, OH 45701 USA

[2] Univ Coll Osteopath Med OU COM, Dept Special Med, Athens, OH 45701 USA

来源：

EXPERT OPINION ON PHARMACOTHERAPY | 2009年 / 10卷 / 17期

关键词：

DPP-4; inhibitors; incretins; insulin secretagogues; type; 2; diabetes; DIPEPTIDYL-PEPTIDASE-IV; TYPE-2; DIABETES-MELLITUS; THERAPY; SAFETY; CARE; PROGRESSION; EFFICACY; POTENT;

D O I：

10.1517/14656560903456046

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Background: Type 2 diabetes (T2DM) has become a worldwide epidemic. Despite a vast array of new compounds to treat T2DM, recommended treatment goals are consistently not achieved in this country thus suggesting a need to increase treatment options. Objective: To review the role of DPP-4 inhibitors in treatment of T2DM with an emphasis on saxagliptin. Methods: The authors discuss the role of this new class of medications in treatment of T2DM, review the current available studies and the unique characteristics of saxagliptin. Results and conclusions: Saxagliptin, a DPP-4 inhibitor, is one of an important new class of compounds, which seems to be particularly safe and effective especially in early treatment of T2DM.

引用

页码：2927 / 2934

页数：8

共 51 条

[1] Synthesis, biological evaluation and structural determination of β-aminoacyl-containing cyclic hydrazine derivatives as dipeptidlyl peptidase IV (DPP-IV) inhibitors [J].

Ahn, Jin Hee ;

Shin, Mi Sik ;

Jun, Mi Ae ;

Jung, Sun Ho ;

Kang, Seung Kyu ;

Kim, Kwang Rok ;

Dal Rhee, Sang ;

Kang, Nam Sook ;

Kim, Sun Young ;

Sohn, Sang-Kwon ;

Kim, Sung Gyu ;

Jin, Mi Sun ;

Lee, Jie Oh ;

Cheon, Hyae Gyeong ;

Kim, Sung Soo .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2007, 17 (09) :2622-2628

[2] National Trends in Treatment of Type 2 Diabetes Mellitus, 1994-2007 [J].

Alexander, G. Caleb ;

Sehgal, Niraj L. ;

Moloney, Rachael M. ;

Stafford, Randall S. .

ARCHIVES OF INTERNAL MEDICINE, 2008, 168 (19) :2088-2094

[3]

*AM DIAB ASS, COSTS DIAB CAR

[4] Efficacy and safety of incretin therapy in type 2 diabetes - Systematic review and meta-analysis [J].

Amori, Renee E. ;

Lau, Joseph ;

Pittas, Anastassios G. .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2007, 298 (02) :194-206

[5]

[Anonymous], CURRENT TOPICS MED C

[6]

[Anonymous], 2009, ONGL SAX PACK INS

[7] Discovery and preclinical profile of saxagliptin (BMS-477118): A highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes [J].

Augeri, DJ ;

Robl, JA ;

Betebenner, DA ;

Magnin, DR ;

Khanna, A ;

Robertson, JG ;

Wang, AY ;

Simpkins, LM ;

Taunk, P ;

Huang, Q ;

Han, SP ;

Abboa-Offei, B ;

Cap, M ;

Xin, L ;

Tao, L ;

Tozzo, E ;

Welzel, GE ;

Egan, DM ;

Marcinkeviciene, J ;

Chang, SY ;

Biller, SA ;

Kirby, MS ;

Parker, RA ;

Hamann, LG .

JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (15) :5025-5037

[8] Systematic review: Comparative effectiveness and safety of oral medications for type 2 diabetes Mellitus [J].

Bolen, Shari ;

Feldman, Leonard ;

Vassy, Jason ;

Wilson, Lisa ;

Yeh, Hsin-Chieh ;

Marinopoulos, Spyriclon ;

Wiley, Crystal ;

Selvin, Elizabeth ;

Wilson, Renee ;

Bass, Eric B. ;

Brancati, Frederick L. .

ANNALS OF INTERNAL MEDICINE, 2007, 147 (06) :386-399

[9]

Boulton DW, 2008, CLIN PHARMACOL THER, V83, pS93

[10]

Boulton DW, 2009, CLIN PHARMACOL THER, V85, pS96

← 1 2 3 4 5 6 →